{'fraction_non_alphanumeric': 0.016139044072004966, 'fraction_numerical': 0.015518311607697082, 'mean_word_length': 5.06015037593985, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
McMaster Conference on Prevention of Rh Immunization 28–30 September, 1977

Since 1966, it has been accepted that Rh immunization following pregnancy can be prevented in most cases by giving a dose of anti-D immunoglobulin (anti-D Ig) to Rhnegative mothers after delivery of any Rhpositive infant and also after any stillbirth or abortion. Ways to make such treatment available for every woman in need of it were reviewed by WHO working groups in 1967 [ l ] and 1970 [2] and their recommendations were adopted in a number of countries where haemolytic disease of the newborn (HDN) caused by anti-D antibodies was a significant cause of perinatal mortality and morbidity. In September 1977 a number of workers from several countries who had participated in establishing and maintaining programmes to prevent Rh immunization by pregnancy met at McMaster University Medical School to review the success of such programmes and to consider what measures might be taken to reduce further the incidence of Rh immunization in pregnancy and of HDN due to anti-D antibodies. In all the countries concerned in recent years, limits have been put on funds available for health services, which may become more stringent in future. The Conference therefore planned to promote economic analyses both of current programmes and of any new measures that might be suggested to prevent Rh immunization. This report reviews data available to the Conference, sets out conclusions and recommendations, and briefly reviews methods and results of economic analyses, which will be published in detail elsewhere by two of the participants.